Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Edwards Lifesciences Corp’s stock clocked out at $75.80, down -0.73% from its previous closing price of $76.36. In other words, the price has decreased by -$0.73 from its previous closing price. On the day, 1.94 million shares were traded.
Ratios:
To gain a deeper understanding of EW’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.40 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 70.23. For the most recent quarter (mrq), Quick Ratio is recorded 3.66 and its Current Ratio is at 4.45. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
Wolfe Research Downgraded its Peer Perform to Underperform on January 16, 2025, while the target price for the stock was maintained at $60.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 30 ’25 when Zovighian Bernard J sold 16,099 shares for $77.21 per share. The transaction valued at 1,243,065 led to the insider holds 9,564 shares of the business.
Zovighian Bernard J sold 967 shares of EW for $74,772 on Jun 03 ’25. The CEO now owns 8,597 shares after completing the transaction at $77.32 per share. On Jun 03 ’25, another insider, Zovighian Bernard J, who serves as the Officer of the company, bought 967 shares for $77.32 each.
Valuation Measures:
As of this moment, Edwards’s Price-to-Earnings (P/E) ratio for their current fiscal year is 50.64, and their Forward P/E ratio for the next fiscal year is 27.51. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.92. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.03 while its Price-to-Book (P/B) ratio in mrq is 4.39.
Stock Price History:
Over the past 52 weeks, EW has reached a high of $95.25, while it has fallen to a 52-week low of $58.93. The 50-Day Moving Average of the stock is 2.09%, while the 200-Day Moving Average is calculated to be 6.41%.
Shares Statistics:
A total of 586.20M shares are outstanding, with a floating share count of 574.70M. Insiders hold about 2.03% of the company’s shares, while institutions hold 87.86% stake in the company.
Earnings Estimates
A comprehensive evaluation of Edwards Lifesciences Corp (EW) is underway, with the input of 26.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.6, with high estimates of $0.65 and low estimates of $0.56.
Analysts are recommending an EPS of between $2.55 and $2.41 for the fiscal current year, implying an average EPS of $2.47. EPS for the following year is $2.75, with 30.0 analysts recommending between $2.93 and $2.61.
Revenue Estimates
In the current quarter, 26 analysts expect revenue to total $1.49B. It ranges from a high estimate of $1.51B to a low estimate of $1.45B. As of the current estimate, Edwards Lifesciences Corp’s year-ago sales were $1.63BFor the next quarter, 26 analysts are estimating revenue of $1.47B. There is a high estimate of $1.5B for the next quarter, whereas the lowest estimate is $1.44B.
A total of 32 analysts have provided revenue estimates for EW’s current fiscal year. The highest revenue estimate was $5.98B, while the lowest revenue estimate was $5.77B, resulting in an average revenue estimate of $5.89B. In the same quarter a year ago, actual revenue was $5.44BBased on 31 analysts’ estimates, the company’s revenue will be $6.45B in the next fiscal year. The high estimate is $6.66B and the low estimate is $6.28B.
